Gilead Sciences Inc's COVID-19 drug remdesivir last year overtook AbbVie Inc's 20-year-old arthritis drug Humira as the medicine that U.S. hospitals spent the most on, according to Vizient Inc, a purchasing group used by about half the nation's hospitals.
Remdesivir, an intravenous antiviral approved early in the pandemic for hospitalized COVID patients and authorized last month for high-risk outpatients, could retain the top spot through mid-2023, according to Vizient's projections.
What does the vaccine cost? Pretty sure it won't make people bankrupt.
Remdesivir, an intravenous antiviral approved early in the pandemic for hospitalized COVID patients and authorized last month for high-risk outpatients, could retain the top spot through mid-2023, according to Vizient's projections.
What does the vaccine cost? Pretty sure it won't make people bankrupt.
I don't have an anger problem, I have an idiot problem.